David Melniczek, MD
Surgery · Jackson, CANPI 1275575664
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,144 of the $1,894 with a category attached, or 60.4%. Davol Inc. accounts for 63.8% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $821 and has fallen 73.8% since, to $216 in 2025. That places this record below the midpoint for surgery clinicians in CA, where the typical reported total is $1,806.
Across 25 payments — averaging $75.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$1K
- TELA Bio, Inc.$458
- Apyx Medical Corporation$152
- Galderma Laboratories, L.p.$38
- Acell, Inc.$21
- Merz North America, Inc.$17
What the payments were for
- Travel & lodging$75040%
- Food & beverage$1,14460%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 12 | $1,208 |
| TELA Bio, Inc. | 7 | $458 |
| Apyx Medical Corporation | 1 | $152 |
| Galderma Laboratories, L.p. | 3 | $38 |
| Acell, Inc. | 1 | $21 |
| Merz North America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,894 in reported general payments places this provider in the 50th percentile of 2,363 surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 47 | $3,205 |
| Celecoxib | 29 | $511 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 31 | $262 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $220 |
| Pantoprazole Sodium | 13 | $204 |
| Gabapentin | 17 | $77 |
| Cephalexin | 13 | $58 |
| Ibuprofen | 16 | $39 |
| Alprazolam | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Other surgery in Jackson
- Timothy ChuterSan Francisco$8.8M
- Santiago HorganSan Diego$2.8M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
- Siew-Ming LeeFresno$1.3M
- Beemen KhalilPalo Alto$1.1M
- John LiphamLos Angeles$942K
- Alexander NedopilLodi$682K
- Barry GardinerSan Ramon$602K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.